London · Delayed Price · Currency is GBP · Price in SEK Hansa Biopharma AB Statistics
Total Valuation
LON:0RC7 has a market cap or net worth of GBP 342.68 million. The enterprise value is 361.81 million.
| Market Cap | 342.68M |
| Enterprise Value | 361.81M |
Important Dates
The last earnings date was Wednesday, February 11, 2026.
| Earnings Date | Feb 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 101.76M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +29.23% |
| Shares Change (QoQ) | +20.06% |
| Owned by Insiders (%) | 5.84% |
| Owned by Institutions (%) | 16.28% |
| Float | 56.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.13 |
| PB Ratio | -50.53 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.48 |
| EV / Sales | 19.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.94
| Current Ratio | 1.94 |
| Quick Ratio | 1.92 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.43 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -33.08% |
| Return on Invested Capital (ROIC) | -48.62% |
| Return on Capital Employed (ROCE) | -68.87% |
| Weighted Average Cost of Capital (WACC) | 13.57% |
| Revenue Per Employee | 134,712 |
| Profits Per Employee | -320,773 |
| Employee Count | 133 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 19.12 |
Taxes
In the past 12 months, LON:0RC7 has paid 182,823 in taxes.
| Income Tax | 182,823 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +67.50% in the last 52 weeks. The beta is 1.84, so LON:0RC7's price volatility has been higher than the market average.
| Beta (5Y) | 1.84 |
| 52-Week Price Change | +67.50% |
| 50-Day Moving Average | 34.38 |
| 200-Day Moving Average | 30.57 |
| Relative Strength Index (RSI) | 66.99 |
| Average Volume (20 Days) | 4,538 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, LON:0RC7 had revenue of GBP 17.92 million and -42.66 million in losses. Loss per share was -0.53.
| Revenue | 17.92M |
| Gross Profit | 11.18M |
| Operating Income | -41.97M |
| Pretax Income | -42.48M |
| Net Income | -42.66M |
| EBITDA | -41.77M |
| EBIT | -41.97M |
| Loss Per Share | -0.53 |
Balance Sheet
The company has 56.51 million in cash and 75.27 million in debt, with a net cash position of -18.76 million.
| Cash & Cash Equivalents | 56.51M |
| Total Debt | 75.27M |
| Net Cash | -18.76M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -6.78M |
| Book Value Per Share | -0.07 |
| Working Capital | 31.11M |
Cash Flow
| Operating Cash Flow | -44.27M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 62.41%, with operating and profit margins of -234.27% and -238.12%.
| Gross Margin | 62.41% |
| Operating Margin | -234.27% |
| Pretax Margin | -237.10% |
| Profit Margin | -238.12% |
| EBITDA Margin | -233.13% |
| EBIT Margin | -234.27% |
| FCF Margin | n/a |
Dividends & Yields
LON:0RC7 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.23% |
| Shareholder Yield | -29.23% |
| Earnings Yield | -12.45% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |